Registration Form • Aug 13, 2020
Registration Form
Open in ViewerOpens in native device viewer
August 13, 2020
Via EDGAR Submission
Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the "Act"), Teva Pharmaceutical Industries Limited (the "Company"), Teva Pharmaceutical Finance Netherlands II B.V. and Teva Pharmaceutical Finance Netherlands III B.V. (collectively, the "Registrants") hereby request acceleration of the effective date of its Registration Statement on Form S-4 (SEC File No. 333-241010) (the "Registration Statement"), to 9:00 a.m., Eastern Time, on August 17, 2020, or as soon thereafter as possible. The Registrants hereby acknowledge their responsibilities under the Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed exchange offer of the securities specified in the Registration Statement.
U.S. Securities and Exchange Commission August 13, 2020 Page 2
Please contact Ross M. Leff of Kirkland & Ellis LLP, special counsel to the Company, at (212) 446-4947, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
| By: | /s/ Eli Kalif |
|---|---|
| Name: Eli Kalif | |
| Title: | Executive Vice President and Chief Financial |
| Officer |
By: Teva Pharmaceuticals Europe B.V., its Managing Director
By: /s/ David Vrhovec
Name: David Vrhovec
Title: Managing Director
By: /s/ Tomer Amitai
Name: Tomer Amitai Title: Managing Director
By: Teva Pharmaceuticals Europe B.V., its Managing Director
By: /s/ David Vrhovec
Name: David Vrhovec Title: Managing Director
By: /s/ Tomer Amitai
Name: Tomer Amitai Title: Managing Director
cc: Ross M. Leff Kirkland & Ellis LLP
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.